tes the CSC-like features of breast cancer cells. Recent studies indicate that a subset 21825001 of cancer cells referred to as cancer stem cells play a critical role in tumor initiation and resistance to anticancer therapy. The tumor cell populations surviving chemo- and radiotherapy are enriched for CSCs and have the phenotypic hallmarks of epithelial-to-mesenchymal transition . The acquisition of EMT program is a critical process for the progression of cancers from local carcinomas to invasive malignancies, which is often associated with the loss of epithelial differentiation and gain of mesenchymal phenotype. A growing body of evidence has demonstrated a molecular link between EMT and self-renewal, suggesting that EMT programs play critical roles in the maintenance and generation of CSCs. Recent studies showed that breast cancer cells undergoing EMT gain CSC properties including the ability to self-renew, tumorigenicity and expression of the CSC phenotype CD44+/CD242/low. TGFb signaling was found to be a potent inducer of EMT that may enhance cancer progression by dedifferentiation of non-CSCs into tumorigenic and invasive CSCs,. However, in contrast to reports demonstrating that TGFb induces expansion of CSCs and promotes tumor growth, TGFb signaling has also been shown to suppress tumorigenesis and reduce the number of CSCs through differentiation in the breast epithelial cell lines derived from MCF10A cells and in clinical breast cancer samples. Recent observations suggest that TGFb inhibits the sphereinitiating CSC population in the MCF7 breast cancer cells. These controversial results may suggest a complex role of TGFb in the regulation of CSCs from the different tumors that may be due to the differential expression of TGFb regulators and effectors in the distinct molecular subtypes of breast cancers. In support of this hypothesis, Kumar and coauthors demonstrated that tissues transglutaminase is a downstream effector of TGFbinduced EMT, and TGFb 
signaling itself failed to induce EMT, CSC phenotype and drug resistance in the cells lacking TG2 expression, including MCF10A and MCF7 cells. Another study confirmed that TGFb signaling induces the formation of tumor-initiating cells only in claudinlow breast cancer cell lines, but not in MCF7 cells. We found that activation of TGFb signaling reduced the sphere formation properties of MCF7 cells in the manner dependent on 14-3-3s phosphorylation. Notably that TGFb-mediated Ganetespib inhibitory effect of 14-3-3s on putative CSC population inversely correlated with an 11325787 effect of TGFb-dependent 14-3-3s phosphorylation on Smad3-dependent transcription. The overexpression of the wild type 14-3-3s and mutant 14-3-3s Ser74Ala proteins had significantly higher impact on TGFb dependent inhibition of putative CSC population than expression of 14-3-3s Ser69Ala mutant protein suggesting that TGFb1 dependent phosphorylation of 14-3-3s at Ser 69 and Ser 74 can play a different role in regulation of CSCs by TGFb1 activation. It is noteworthy that overexpression of the double mutant 14-3-3s Ser69/74Ala protein has an inhibitory effect on the putative CSC population even without disturbing the Smad3-dependent transcription. This observation can potentially suggest that abrogation of TGFb1 dependent phosphorylation of 14-3-3s at two sites can results in the involvement of 14-3-3s in the alternative, Smad3 independent routes of CSC regulation via TGFb1 signaling network. Resistance to radiation therapy has been reported to